|
Market Closed –
|
5-day change | 1st Jan Change | ||
|
39.24 USD |
+4.06% | -2.17% | -15.56% | |
Published on 05/05/2025 at 07:34
This article is reserved for members Unlock the article: REGISTER NOW!
© MT Newswires – 2025
|
Twist Bioscience Fiscal Q2 Loss Narrows, Revenue Rises; 2025 Sales Outlook Maintained |
07:34am |
MT |
|
(TWST) Twist Bioscience Expects Fiscal 2025 Total Revenue Range $372M – $379M, vs. FactSet Est of $375.8M |
07:27am |
MT |
|
(TWST) Twist Bioscience Expects Q3 Revenue Range $94M – $97M, vs. FactSet Est of $95.5M |
07:26am |
MT |
|
Earnings Flash (TWST) Twist Bioscience Posts Fiscal Q2 Revenue $92.8M, vs. FactSet Est of $92M |
07:26am |
MT |
|
Earnings Flash (TWST) Twist Bioscience Posts Fiscal Q2 Net Loss $0.66 a Share, vs. FactSet Est of $0.58 Loss |
07:25am |
MT |
|
Twist Bioscience Corporation Expands Universal Adapter Portfolio with Launch of High Throughput UDI Adapter System |
Apr. 24 |
CI |
|
Twist Bioscience Corporation and Curio Genomics Collaborate to Accelerate and Streamline NGS Adoption in Agrigenomics |
Mar. 31 |
CI |
|
Twist Bioscience Corporation Presents at Barclays 27th Annual Global Healthcare Conference 2025, Mar-12-2025 08:30 AM |
Mar. 12 |
|
|
Twist Bioscience Corporation Offers Clonal Genes for Global Academic Researchers At Express Speed for No Extra Cost |
Mar. 11 |
CI |
|
Twist Bioscience Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) |
Feb. 19 |
RE |
|
Gobal markets live: Meta, Starbucks, Nvidia, Unicredit, ABB… |
Feb. 03 |
 |
|
The art of the tariff |
Feb. 03 |
|
|
Twist Bioscience Corporation, Q1 2025 Earnings Call, Feb 03, 2025 |
Feb. 03 |
|
|
Twist Bioscience’s Fiscal Q1 Loss Narrows, Revenue Rises; Fiscal 2025 Sales Guidance Lifted |
Feb. 03 |
MT |
|
Twist Bioscience Corp Reports QTRLY Revenue Of $88.7 Million |
Feb. 03 |
RE |
|
(TWST) Twist Bioscience Expects Fiscal 2025 Revenue Range $372 Million – $379 Million, vs. FactSet Est of $373.3 Million |
Feb. 03 |
MT |
|
(TWST) Twist Bioscience Expects Fiscal Q2 Revenue Range $91 Million – $93 Million, vs. FactSet Est of $90.9 Million |
Feb. 03 |
MT |
|
Earnings Flash (TWST) Twist Bioscience Posts Fiscal Q1 Revenue $88.7 Million, vs. FactSet Est of $87 Million |
Feb. 03 |
MT |
|
Earnings Flash (TWST) Twist Bioscience Posts Fiscal Q1 Net Loss $-0.53 a Share, vs. FactSet Est of $-0.62 Loss |
Feb. 03 |
MT |
|
Twist Bioscience Corporation Provides Earnings Guidance for the Second Quarter of 2025 |
Feb. 03 |
CI |
|
Twist Bioscience Corporation Revises Earnings Guidance for the Year 2025 |
Feb. 03 |
CI |
|
Twist Bioscience Corporation Reports Earnings Results for the First Quarter Ended December 31, 2024 |
Feb. 03 |
CI |
|
Twist Bioscience Corporation Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-13-2025 05:15 PM |
Jan. 13 |
|
|
Wolfe Initiates Twist Bioscience at Outperform With $60 Price Target |
Dec. 13 |
MT |
|
Twist Bioscience Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended September 30, 2024 |
Nov. 18 |
CI |
TWST: Dynamic Chart
Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company’s platform’s core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. The Company leverages its technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation and antibody libraries for drug discovery and development. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The Company also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. It is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. It makes products for use across many industries, including healthcare, industrial chemicals, agriculture and academic research.
More about the company
Buy
Average target price
50.74USD
Spread / Average Target
+29.31%
Consensus
Quarterly revenue – Rate of surprise
Select your edition
All financial news and data tailored to specific country editions
